Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Expenditures (2017 - 2026)

Denali Therapeutics has reported Capital Expenditures over the past 9 years, most recently at $1.5 million for Q4 2025.

  • Quarterly Capital Expenditures fell 70.07% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.5 million through Dec 2025, down 40.28% year-over-year, with the annual reading at $9.5 million for FY2025, 40.28% down from the prior year.
  • Capital Expenditures was $1.5 million for Q4 2025 at Denali Therapeutics, up from -$1.4 million in the prior quarter.
  • Over five years, Capital Expenditures peaked at $10.1 million in Q3 2023 and troughed at -$2.2 million in Q2 2023.
  • The 5-year median for Capital Expenditures is $2.2 million (2024), against an average of $2.5 million.
  • The largest YoY upside for Capital Expenditures was 27475.68% in 2023 against a maximum downside of 1168.12% in 2023.
  • A 5-year view of Capital Expenditures shows it stood at $3.1 million in 2021, then tumbled by 61.35% to $1.2 million in 2022, then surged by 89.41% to $2.2 million in 2023, then soared by 127.83% to $5.1 million in 2024, then crashed by 70.07% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Capital Expenditures are $1.5 million (Q4 2025), -$1.4 million (Q3 2025), and $8.9 million (Q2 2025).